Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
58 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Cerebral Palsy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Cerebral Palsy - Pipeline Review, H2 2014', provides an overview of the Cerebral Palsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cerebral Palsy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cerebral Palsy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cerebral Palsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cerebral Palsy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cerebral Palsy Overview 6 Therapeutics Development 7 Pipeline Products for Cerebral Palsy - Overview 7 Pipeline Products for Cerebral Palsy - Comparative Analysis 8 Cerebral Palsy - Therapeutics under Development by Companies 9 Cerebral Palsy - Therapeutics under Investigation by Universities/Institutes 10 Cerebral Palsy - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Cerebral Palsy - Products under Development by Companies 14 Cerebral Palsy - Products under Investigation by Universities/Institutes 15 Cerebral Palsy - Companies Involved in Therapeutics Development 16 Allergan, Inc. 16 Acorda Therapeutics, Inc. 17 Neuralstem, Inc. 18 CHA Bio & Diostech Co., Ltd. 19 K-Stemcell Co., Ltd. 20 Cell Cure Neurosciences, Ltd. 21 Cellular Biomedicine Group, Inc. 22 Cerebral Palsy - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 onabotulinumtoxin A - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 dalfampridine ER - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Stem Cell Therapy for Gastrointestinal, CNS and Endocrine and Metabolic Disorders - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Astrostem - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Stem Cell Therapy for Central Nervous System Disorders - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 NSI-566 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 NeurArrest - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Human Umbilical Cord Derived Mesenchymal Progenitor Cells - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Stem Cell Therapy for Cerebral Palsy - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Cerebral Palsy - Recent Pipeline Updates 46 Cerebral Palsy - Product Development Milestones 56 Featured News & Press Releases 56 Feb 08, 2013: RNL BIO Files Investigational New Drug Application With KFDA For Phase II/III Clinical Trial Using Astrostem To Treat Cerebral Palsy 56 Feb 26, 2007: Epivax Funded To Advance Research On A New, Improved "Botox" 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 58 Disclaimer 58
List of Tables Number of Products under Development for Cerebral Palsy, H2 2014 7 Number of Products under Development for Cerebral Palsy - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Cerebral Palsy - Pipeline by Allergan, Inc., H2 2014 16 Cerebral Palsy - Pipeline by Acorda Therapeutics, Inc., H2 2014 17 Cerebral Palsy - Pipeline by Neuralstem, Inc., H2 2014 18 Cerebral Palsy - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2014 19 Cerebral Palsy - Pipeline by K-Stemcell Co., Ltd., H2 2014 20 Cerebral Palsy - Pipeline by Cell Cure Neurosciences, Ltd., H2 2014 21 Cerebral Palsy - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 22 Assessment by Monotherapy Products, H2 2014 23 Number of Products by Stage and Target, H2 2014 25 Number of Products by Stage and Mechanism of Action, H2 2014 27 Number of Products by Stage and Route of Administration, H2 2014 29 Number of Products by Stage and Molecule Type, H2 2014 31 Cerebral Palsy Therapeutics - Recent Pipeline Updates, H2 2014 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.